BioMarin Pharmaceutical (NASDAQ:BMRN) Issues Earnings Results

BioMarin Pharmaceutical (NASDAQ:BMRN) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.80 by ($1.04), Briefing.com reports. The firm had revenue of $874.57 million for the quarter, compared to analysts’ expectations of $834.32 million. BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. BioMarin Pharmaceutical’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.92 EPS.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• BioMarin reported strong 2025 results with total revenue up 13% to $3.22 billion, Q4 revenue of $875 million, non‑GAAP EPS of $3.15 and operating cash flow of $828 million (up 45%), and provided 2026 guidance (ex‑Amicus) of $3.325–$3.425 billion revenue and non‑GAAP EPS of $4.95–$5.15 with ~40% organic operating margin.
• The announced Amicus acquisition (expected to close in Q2 2026) is positioned to add Galafold, Pombiliti and Opfolda, management secured ~$3.7 billion of financing and expects the deal to materially uplift revenue and patient reach after close despite modest 2026 dilution.
• BioMarin withdrew Roctavian from the market and booked ~$240 million of Q4 GAAP special items, including an inventory write‑off (about half) that is not excluded from non‑GAAP, pressuring reported GAAP results.
• Voxzogo continues driving growth (26% FY to $927 million, ~73% ex‑US, >5,000 patients treated); management plans a full FDA approval submission (adult height and broader outcomes) and is pursuing a hypochondroplasia expansion that could add new indications.
• Revenue cadence is uneven—Q4 benefited from an unusual ~$30 million government order and stocking increases that are unlikely to repeat, and management expects Q1 2026 to be the lowest quarter with some market access renegotiations potentially weighing on near‑term growth.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $62.92 on Tuesday. BioMarin Pharmaceutical has a 52 week low of $50.76 and a 52 week high of $73.51. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10. The company has a fifty day simple moving average of $58.31 and a two-hundred day simple moving average of $56.04. The firm has a market capitalization of $12.09 billion, a P/E ratio of 23.65, a price-to-earnings-growth ratio of 0.70 and a beta of 0.26.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BMRN. CIBC Private Wealth Group LLC increased its stake in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 179 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth approximately $40,000. Parallel Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares during the last quarter. Meeder Asset Management Inc. increased its position in shares of BioMarin Pharmaceutical by 1,974.1% during the 4th quarter. Meeder Asset Management Inc. now owns 1,763 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,678 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new stake in BioMarin Pharmaceutical during the 4th quarter valued at $201,000. Institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Piper Sandler dropped their target price on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Morgan Stanley dropped their price objective on BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research note on Tuesday, October 28th. HC Wainwright lifted their target price on BioMarin Pharmaceutical from $55.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, December 22nd. Stifel Nicolaus reissued a “hold” rating and issued a $61.00 price target (down from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. Finally, Tudor Pickering set a $88.00 price objective on shares of BioMarin Pharmaceutical in a report on Monday, November 3rd. Fourteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.65.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Announced definitive agreement to acquire Amicus Therapeutics, bringing marketed assets (Galafold) and late‑stage programs (Pombiliti + Opfolda) that management says will materially diversify and accelerate revenue growth; expected close Q2’26. PR Newswire: Amicus Acquisition
• Positive Sentiment: Underlying revenue momentum: Q4 total revenues up ~17% Y/Y and full‑year 2025 revenues rose ~13% to $3.2B, with VOXZOGO showing strong double‑digit growth—key for near‑term top‑line expansion. PR Newswire: Q4/FY Results
• Positive Sentiment: Analyst backing: TD Cowen kept a Buy rating and $120 PT citing the quarter and strategic deal; Bank of America reiterated Buy (cut PT to $97) but highlights pipeline upside that offsets competitive pressures on VOXZOGO. TipRanks: TD Cowen TipRanks: BofA
• Neutral Sentiment: 2026 guidance excludes any post‑close contribution from Amicus: company gave revenue guidance of roughly $3.3–$3.4B (vs. consensus ~ $3.4B), so the near‑term outlook may look conservative until the deal closes and contributions are modeled. PR Newswire: Guidance
• Neutral Sentiment: Mixed earnings signal: multiple outlets highlight revenue beats, but reported EPS figures and their treatment (GAAP vs. adjusted, one‑offs) vary across publications — investors should review the earnings slides and call transcript for reconciliation. Zacks: Q4 Beat Seeking Alpha: Call Transcript
• Negative Sentiment: Market reaction and near‑term pressure: shares have moved lower as investors digest mixed EPS metrics, the conservative guidance baseline (pre‑Amicus), and potential integration uncertainty tied to the Amicus transaction. Investing.com: Shares Edge Lower

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.